Global ENT Disorder Treatment Market Size study & Forecast, by Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), by Organ (Throat, Ear, Nose), by End User (Hospital and clinics, Homecare Settings, Others) and Regional Analysis, 2022-2029
Global ENT Disorder Treatment Market is valued approximately USD 2.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. ENT Disorder refers to infections associated with ear, nose and throat that caused by bacteria and viruses. Ear infection can cause hearing loss, earache, discharge from ear. Whereas nose & throat disorders can cause sore throat, runny nose, snoring, sleep apnea, and breathing difficulty among others. Moreover, there are different treatment options available for ENT disorders including antibiotics, anti- inflammatory drugs etc. The increasing number of geriatric individuals and growing prevalence of infectious diseases as well as strategic initiatives from leading market players are key factors accelerating the market growth.
According to the World Health Organization (WHO) – in 2019, globally approximately 2.6 million individuals lost their lives due to lower respiratory infections. Moreover, as per Australian Institute of Health and Welfare estimates – in financial year 2020–21, Australia witnessed more than 324,000 hospitalizations for infectious diseases, out of which around 94% were for non-notifiable diseases. Also, growing pollution levels worldwide and rising healthcare spending in developing regions would create lucrative growth prospectus for the market over the forecast period. However, the high cost of medical devices impedes the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global ENT Disorder Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as presence of leading market players and growing prevalence of infectious diseases in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population as well as increasing incidences of respiratory disorders in the region.
Major market player included in this report are:
Sanofi
Novartis
GSK
Pfizer
Vitaris
Sun Pharma
AstraZeneca
Cipla
AurbindoPharma
Teva Pharmaceuticals
Recent Developments in the Market:
In August 2020, Hyderabad, India based Dr Reddy’s Laboratories launched a generic version of Ciprodex in the United States. This new drug is intended for treatment of ear infections.
In October 2021, Cipla Pharmaceuticals launched an anti-viral nasal spray named Naselin. This new spray contains 'povidone Iodine' that protects against coronavirus and respiratory tract infections.
Global ENT Disorder Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Type, Organ, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type
Antibiotics Drugs
Anti-Inflammatory Drugs
Others
By Organ
Throat
Ear
Nose
By End User
Hospital and clinics
Homecare Settings
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Companies Mentioned
Sanofi
Novartis
GSK
Pfizer
Vitaris
Sun Pharma
AstraZeneca
Cipla
AurbindoPharma
Teva Pharmaceuticals
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook